973PD - Dose-dense weekly paclitaxel and carboplatin is more cost-effective than bevacizumab plus triweekly paclitaxel and carboplatin for the primary treat...

Date 30 September 2012
Event ESMO Congress 2012
Session Gynecological cancers
Topics Anti-Cancer Agents & Biologic Therapy
Ovarian Cancer
Bioethics, Legal, and Economic Issues
Presenter Kenichi Harano
Authors K. Harano1, T. Shiroiwa2, M. Watanabe3, K. Suzuki3, T. Fukuda4, S. Watanabe3, N. Katsumata1
  • 1Department Of Medical Oncology, Nippon Medical School Musashikosugi Hospital, 211-8533 - Kawasaki city/JP
  • 2Department Of Hygiene And Public Health, Teikyo University School of Medicine, Tokyo/JP
  • 3Consulting Division, Global Health Consulting Japan, Tokyo/JP
  • 4Center For Public Health Informatics, National Institute of Public Health, Saitama/JP

Abstract

Purpose

To determine whether dose-dense weekly paclitaxel and carboplatin (ddPC) is cost effective compared to bevacizumab plus triweekly paclitaxel and carboplatin (PCB) for the primary treatment of advanced ovarian cancer.

Methods

A cost-effectiveness analysis compared three treatments: 6 cycles of paclitaxel and carboplatin (PC), 6 cycles of PC plus bevacizumab followed by 12 cycles of maintenance bevacizumab (PCB), and 6 cycles of dose-dense weekly paclitaxel and carboplatin (ddPC). Data were taken from reported results of ICON7 (PC and PCB) and JGOG3016 (ddPC). Actual and estimated costs of treatment plus costs of complications were established for each regimen. Progression-free survival and rates of complications were estimated based on the results of clinical trials. Incremental cost-effective ratios (ICER) per progression-free life-year saved (PFLYS) were estimated.

Results

The ICER for ddPC was $5,000 per PFLYS compared to PC. For PCB compared to PC, the ICER was $285,000 per PFLYS. When compared simultaneously, PCB was more costly and less effective than ddPC.

Conclusions

In this model, dose-dense weekly paclitaxel and carboplatin is more cost effective than PCB for the treatment of advanced ovarian cancer.

Disclosure

All authors have declared no conflicts of interest.